tirzepatide trial obesity without diabetes surmount-1 weight loss non-diabetic For the first time, and semaglutide were put in SURMOUNT-MMO: First trial on tirzepatide

It works by: Suppresses appetite Slows gastric emptying Improves insulin sensitivity Reduces sugar cravings

Peer-review model: Single blind Peer-review started: October 17, 2023 First decision: October 31, 2023 Article in press: December 2, 2023 Specialty type: Gastroenterology and hepatology Country/Territory of origin: Australia Peer-review reports scientific quality classification Grade A (Excellent): A Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0 P-Reviewer: Barone M, Italy

Glutathione levels decline with age, chronic disease, and oxidative stress, contributing to cellular vulnerability [7]

1 2 "Melanoma"